2seventy bio, Inc. (TSVT)
Market Closed
13 May, 20:00
NASDAQ (NGS) NASDAQ (NGS) Primary 
XMEX $
5. 00
0
0%
$
266.14M Market Cap
- P/E Ratio
- Div Yield
1.16M Volume
-1.94 Eps
$ 5
Previous Close Want to track TSVT and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
TSVT closed Tuesday higher at $5, an increase of 0% from Monday's close, completing a monthly increase of 0% or $5. Over the past 12 months, TSVT stock gained 0%.
TSVT is not paying dividends to its shareholders.
The last earnings report, released on May 01, 2025, exceeded the consensus estimates by 0.81%. On average, the company has surpassed earnings expectations by 0.2866%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 2 different exchanges and in various currencies, with the primary listing on NASDAQ (NGS) (USD).
2seventy bio, Inc. (TSVT) Upgraded to Buy: Here's Why
2seventy bio, Inc. (TSVT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks | 1 year ago
TSVT Up on Acquisition Agreement With BMY for $286 Million
2seventy bio agrees to be acquired by partner BMY for $286 million. Shares gain.
Zacks | 1 year ago
2seventy bio, Inc. (TSVT) Upgraded to Buy: Here's What You Should Know
2seventy bio, Inc. (TSVT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks | 1 year ago
2seventy bio, Inc. (TSVT) FAQ
What is the stock price today?
The current price is $5.00.
On which exchange is it traded?
2seventy bio, Inc. is listed on NASDAQ (NGS).
What is its stock symbol?
The ticker symbol is TSVT.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 266.14M.
Has 2seventy bio, Inc. ever had a stock split?
No, there has never been a stock split.
2seventy bio, Inc. Profile
| Biotechnology Industry | Healthcare Sector | William D. Baird III, CEO | NASDAQ (NGS) Exchange | 901384107 CUSIP |
| US Country | 65 Employees | - Last Dividend | - Last Split | 3 Nov 2021 IPO Date |
2seventy bio, Inc. operates as a biotechnology firm specializing in cell and gene therapies, with a primary mission to discover, develop, and commercialize advanced cancer treatments within the U.S. Its pipeline notably includes idecabtagene vicleucel, marketed as ide-cel or Abecma, and bb21217, both of which are CAR-T cell therapeutic candidates specifically designed to address multiple myeloma. The company also maintains a strategic partnership with Bristol-Myers Squibb Company. Founded in 2021, its corporate headquarters are situated in Cambridge, Massachusetts.
Contact Information
Address: 60 Binney Street
Phone: 339 499 9300
Website: https://www.2seventybio.com
